事件：三生制药发布2025 年上半年业绩。公司2025H1 实现收入43.55 亿元，同比-1.07%，扣非归母净利润13.58 亿元，同比+19.13%；研发费用5.48 亿元，同比+15.13%；销售费用16.16 亿元，同比+1.38%；管理费用2.83 亿元，同比+40.80%。内生经营业务增长稳定。2025 年上半年，三生制药实现收入43.55 亿元，同比-1.07%；归母净利润13.6...
Source Link事件：三生制药发布2025 年上半年业绩。公司2025H1 实现收入43.55 亿元，同比-1.07%，扣非归母净利润13.58 亿元，同比+19.13%；研发费用5.48 亿元，同比+15.13%；销售费用16.16 亿元，同比+1.38%；管理费用2.83 亿元，同比+40.80%。内生经营业务增长稳定。2025 年上半年，三生制药实现收入43.55 亿元，同比-1.07%；归母净利润13.6...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.